This dyslipidemia is primarily attributed to the downregulation of LDL receptor expression and reduced activity of cholesterol 7α-hydroxylase due to altered thyroid hormone levels, leading to decreased hepatic clearance of LDL and impaired conversion and excretion of CHOL (38). The gene discussed is CYP7A1; the disease is metabolic syndrome.